Top 10 Oncology Capital Raises and Investors in the U.S. – July 1st-15th, 2025
Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Lixte Biotechnology Holdings, a biopharmaceutical company dedicated to improving patients’ lives by developing a drug class called Protein Phosphatase 2A inhibitors, received approximately $5.05 million in development capital through a private placement.
- X4 Pharmaceuticals, a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system, received $40 million in development capital from Lincoln Park Capital through a private placement.
Merger/Acquisition and Corporate
-
- Akoya Biosciences, a life sciences technology company, was acquired by Quanterix.
- SpringWorks Therapeutics, a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer, was acquired by Merck for $3.4 billion.
Later Stage VC
-
- Decoy Therapeutics, a company developing immunotherapy products to address cancer treatment challenges, raised $1.2 million of venture funding in the form of convertible debt.
- Emit Imaging, an imaging technology that monitors drug distribution and protein expression, raised $7.10 million of venture funding.
- General Oncology, a clinical-stage biopharma company that manufactures medicines for cancer, raised $10.88 million of venture funding.
- Imagene, AI-based oncology diagnostics software for accelerating biomarker detection and supporting precision cancer treatment, raised $23 million in Series B venture funding.
Early Stage VC
-
- Actithera, a molecular radiotherapeutic company for biotechnology research services, raised $75.5 million of Series A venture funding in a deal led by M Ventures, 4BIO Capital, Sofinnova Partners and Hadean Ventures.
Seed
-
- Defiant Health, a virtual breast health clinic that accelerates expert diagnosis and treatment for breast cancer, raised $3.83 million in Seed funding from Hannah Grey Ventures, and Amboy Street Ventures, other investors.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
